Journal
INTERNATIONAL JOURNAL OF STD & AIDS
Volume 22, Issue 5, Pages 294-295Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1258/ijsa.2009.009166
Keywords
tipranavir; enfuvirtide; pregnancy; pharmacokinetics; HIV; mother-to-child transmission; antiretroviral therapy
Categories
Ask authors/readers for more resources
The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation. Tipranavir levels were in the therapeutic range and the cord blood concentration at delivery was relatively high when compared with other protease inhibitors. No enfuvirtide was detected in the fetal compartment. Tipranavir and enfuvirtide were successfully used in pregnancy, but possible toxicities must be kept in mind.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available